Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Myasthenia Gravis →Neurological & Neuromuscular

Cemdisiran for Generalized myasthenia gravis (anti-AChR antibody-positive adults)

Regeneron · NDA
FDA decision due
November 2026
Exact date not public
Email me the day the FDA decides on Cemdisiran

One email when the decision is public, with what it means in plain language. You'll also get new trials and FDA news for Myasthenia Gravis. Unsubscribe anytime.

You'll get, for Myasthenia Gravis:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

The FDA is expected to decide on Cemdisiran for Generalized myasthenia gravis (anti-AChR antibody-positive adults) in November 2026, under an NDA from Regeneron.

What the FDA is deciding on Cemdisiran for Generalized myasthenia gravis

The FDA is reviewing Regeneron's application to approve Cemdisiran for generalized myasthenia gravis (anti-AChR antibody-positive adults).

An siRNA that lowers the liver's production of complement protein C5, injected under the skin every 12 weeks. The FDA granted Priority Review with a target action date in November 2026; Regeneron has not disclosed the exact day. In the Phase 3 NIMBLE trial, published in The Lancet, MG-ADL scores improved 2.3 points more than placebo at week 24.

If approved, it would join Soliris, its biosimilars, Ultomiris and Zilbrysq as a C5-targeting option for AChR-positive adults.

Who the Cemdisiran decision matters to

Myasthenia gravis is a chronic autoimmune neuromuscular disorder causing muscle weakness and rapid fatigue. Antibodies attack acetylcholine receptors at the neuromuscular junction, preventing proper muscle contraction.

The condition is manageable with medications and other treatments that suppress the immune response.

Prevalence: 1 in 5,000 people. See our full Myasthenia Gravis page for current treatments, recruiting trials, and community resources.

How Cemdisiran works

Cemdisiran: small interfering RNA (siRNA) that lowers the body's production of complement component 5 (C5). Our full Cemdisiran profile covers how it works, side effects in plain language, and its trial history.

What an approval or a rejection of Cemdisiran would mean

An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.

A complete response letter would mean the FDA declined to approve in the application's current form. The letter describes what the FDA wants addressed, and the company then decides whether to resubmit, run more studies or stop. Either way, this page updates with the outcome and what it means.

Where Myasthenia Gravis treatment stands today

FDA approved for Myasthenia Gravis (8)
Soliris (eculizumab)Complement C5 inhibitorsince 2017Vyvgart (efgartigimod alfa)FcRn inhibitorsince 2021Ultomiris (ravulizumab)Complement inhibitorsince 2022Rystiggo (rozanolixizumab)FcRn inhibitorsince 2023Zilbrysq (zilucoplan)Complement inhibitorsince 2023Uplizna (inebilizumab)Anti-CD19 monoclonal antibodysince 2025Imaavy (nipocalimab)FcRn inhibitorsince 2025Klygefa (gefurulimab)Complement C5 inhibitor (bispecific nanobody)since 2026
Coming next: under FDA review or in Phase 3 (2)
ImeroprubartFcRn blocker (investigational)Phase 3 trialmivocabtagene autoleucelCD19-directed CAR T-cell therapyPhase 3 trial
Read our full Myasthenia Gravis treatment summary

Myasthenia gravis treatment options are expanding rapidly with new targeted therapies entering clinical trials. FcRn inhibitors reduce pathogenic antibody levels, while complement inhibitors block the destruction of acetylcholine receptors.

Another FcRn blocker, nipocalimab (Imaavy), was FDA approved in April 2025 for generalized MG in adults and children 12 and older who are AChR or MuSK antibody positive, and is given by IV infusion every 2 weeks after a first loading dose. Trials are designed for specific antibody subtypes, with the most options available for AChR-positive patients.

MuSK-positive patients are increasingly included in FcRn inhibitor and complement studies, while seronegative MG patients have the fewest dedicated trial options. Pyridostigmine (Mestinon) is almost always allowed during trials.

If you are on a targeted therapy like Vyvgart or Soliris and want to join a new trial, expect a washout period of 4 weeks to 4 months depending on the drug class.

Your MG-ADL score, MGFA classification, and recent flare history all factor into trial eligibility. The Myasthenia Gravis Foundation of America tracks trial opportunities.

Your neuromuscular specialist can help determine which emerging therapies match your antibody subtype, disease severity, and current medication regimen.

The Myasthenia Gravis page has every treatment and trial →

Meanwhile, 118 Myasthenia Gravis studies are recruiting or not yet recruiting

Whatever the FDA decides here, research on Myasthenia Gravis does not stop. The most recently updated:

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad
Treatment trial · NCT06463587 · has US sites
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
Treatment trial · NCT07304154 · has US sites
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
Observational study, no treatment given · NCT06298565 · has US sites
See all 118 open studies →

Earlier-stage drugs Trial Friend tracks for Myasthenia Gravis

BHV-1450 · preclinical
Get an email the day the FDA decides on Cemdisiran

We'll email you when the decision is public, with what it means in plain language, and when new trials open for Myasthenia Gravis. Unsubscribe anytime.

You'll get, for Myasthenia Gravis:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Or get every FDA decision, for any condition

One email the day each decision on our calendar is announced, for any condition. No trial alerts and no condition to pick.

We never share your email. Stop anytime from the link in every email. Privacy policy

Frequently asked questions

When will the FDA decide on Cemdisiran?

Regeneron expects a decision in November 2026 but has not given an exact date.

Who disclosed it: Regeneron. The FDA does not publish these dates.

Can it move: the FDA can act early, and a major amendment to the application can push the date back 3 months.

Source: Regeneron press release

What is Cemdisiran being reviewed for?

Regeneron submitted an NDA for Cemdisiran in Generalized myasthenia gravis (anti-AChR antibody-positive adults).

What to know: An siRNA that lowers the liver's production of complement protein C5, injected under the skin every 12 weeks. The FDA granted Priority Review with a target action date in November 2026; Regeneron has not disclosed the exact day. In the Phase 3 NIMBLE trial, published in The Lancet, MG-ADL scores improved 2.3 points more than placebo at week 24. If approved, it would join Soliris, its biosimilars, Ultomiris and Zilbrysq as a C5-targeting option for AChR-positive adults.

How it works: Small interfering RNA (siRNA) that lowers the body's production of complement component 5 (C5).

More: the Cemdisiran drug page explains it in plain language.

Is there already an FDA-approved treatment for Myasthenia Gravis?

Yes. Trial Friend's drug list includes 8 FDA-approved drugs for Myasthenia Gravis.

Approved: Soliris (eculizumab), Vyvgart (efgartigimod alfa), Ultomiris (ravulizumab), Rystiggo (rozanolixizumab), Zilbrysq (zilucoplan), Uplizna (inebilizumab), Imaavy (nipocalimab), Klygefa (gefurulimab).

Also coming: Imeroprubart, mivocabtagene autoleucel.

Check: the Myasthenia Gravis page also searches FDA drug labels for approved treatments.

What did the Cemdisiran trials show?

NIMBLE (NCT05070858) is a double-blind, placebo-controlled Phase 3 trial run at 86 centers in 13 countries in adults with generalized myasthenia gravis, anti-AChR or anti-LRP4 antibodies and an MG-ADL score of 6 or more. It randomized 284 people to 4 groups for 24 weeks: cemdisiran 600mg every 12 weeks (79), pozelimab 200mg every 4 weeks (50), cemdisiran 200mg plus pozelimab 200mg every 4 weeks (80), or placebo (75).

More: the Cemdisiran drug page has the full trial history and sources.

What are the side effects of Cemdisiran?

Cemdisiran has no US label yet, so the warnings an FDA label would carry are not set. In NIMBLE's 24-week double-blind period, 69% of people on cemdisiran (54 of 78) had at least 1 adverse event, against 77% on placebo (54 of 70).

More: the Cemdisiran drug page has the safety details reported so far.

Can I get Cemdisiran before the FDA decides?

Usually only through a clinical trial or an expanded access program, and the company decides whether to offer one.

Trials: 118 Myasthenia Gravis studies are recruiting or not yet recruiting. See them.

Check your fit: Match Me compares your details with every open trial.

Expanded access: your doctor can ask Regeneron directly. Registered programs are listed on ClinicalTrials.gov.

How much will Cemdisiran cost?

Regeneron has not announced a price. Drugmakers usually set it around approval.

Help paying: drugmaker programs and charity funds usually open at launch.

Find help: the patient assistance finder lists programs by insurance type.

What happens after the Cemdisiran decision?

This page updates with the outcome the day it is announced.

If approved: getting the drug still takes time. Specialty pharmacy setup, insurance review and patient assistance often take weeks. Our guide covers what families can do on day 1.

If not approved: a complete response letter means the FDA declined the application in its current form. Many are about manufacturing or how data were presented, and companies often resubmit.

Where this date comes from

The FDA does not publish PDUFA dates; companies disclose them. This one comes from Regeneron press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.